Roche scraps two Ionis-partnered Huntington’s drugs
Data ReadoutnegativetominersenNegative
AI Analysis
Summary
Roche terminated development of two Ionis-partnered Huntington's disease drugs after tominersen failed to show disease progression delay in a clinical trial and a second candidate was scrapped due to animal safety signals.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Tominersen failed to delay disease progression in one trial. A second Huntington's drug study was terminated due to safety signal in animal testing.
Importance:8/10
Sentiment:
-0.95
Huntington's diseaseclinical failurepartnershipdrug terminationsafety concern
Read the original article
Published by BioPharma Dive on July 9, 2026 8:53 PM